Sökning: WFRF:(Cequier Angel) >
Use, patient select...
Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries
-
- Danchin, Nicolas (författare)
- Paris Descartes University
-
- Lettino, Maddalena (författare)
- Humanitas Research Hospital
-
- Zeymer, Uwe (författare)
- Institute for Cardiac Arrest Research, Ludwigshafen
-
visa fler...
-
- Widimsky, Petr (författare)
- Charles University in Prague
-
- Bardaji, Alfredo (författare)
- Hospital Joan XXIII
-
- Barrabes, Jose A. (författare)
- Vall d'Hebron University Hospital
-
- Cequier, Angel (författare)
- Bellvitge University Hospital-IDIBELL
-
- Claeys, Marc J. (författare)
- Antwerp University Hospital
-
- De Luca, Leonardo (författare)
- European Hospital
-
- Dörler, Jakob (författare)
- Medical University of Innsbruck
-
- Erlinge, David (författare)
- Lund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Molekylär kardiologi,Forskargrupper vid Lunds universitet,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Molecular Cardiology,Lund University Research Groups,Skåne University Hospital
-
- Erne, Paul (författare)
- University of Zurich
-
- Goldstein, Patrick (författare)
- Lille University Hospital
-
- Koul, Sasha M. (författare)
- Skåne University Hospital
-
- Lemesle, Gilles (författare)
- Lille University Hospital
-
- Lüscher, Thomas F. (författare)
- University Hospital of Zurich
-
- Matter, Christian M. (författare)
- University Hospital of Zurich
-
- Montalescot, Gilles (författare)
- Pitié-Salpêtrière University Hospital
-
- Radovanovic, Dragana (författare)
- University of Zurich
-
- Sendón, Jose Lopez (författare)
- University Hospital La Paz
-
- Tousek, Petr (författare)
- Charles University in Prague
-
- Weidinger, Franz (författare)
- Hospital Rudolfstiftung
-
- Weston, Clive F.M. (författare)
- Swansea University
-
- Zaman, Azfar (författare)
- University of Newcastle upon Tyne
-
- Andell, Pontus (författare)
- Skåne University Hospital
-
- Li, Jin (författare)
- University Hospital of Zurich
-
- Jukema, J. Wouter (författare)
- Leiden University Medical Centre
-
visa färre...
-
(creator_code:org_t)
-
- 2016-01-27
- 2016
- Engelska 16 s.
-
Ingår i: European Heart Journal - Cardiovascular Pharmacotherapy. - : Oxford University Press (OUP). - 2055-6837 .- 2055-6845. ; 2:3, s. 152-167
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://academic.oup...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Aims Among acute coronary syndromes (ACS), ST-segment elevation myocardial infarction (STEMI) has the most severe early clinical course. We aimed to describe the effectiveness and safety of P2Y12 receptor inhibitors in patients with STEMI based on the data from contemporary European ACS registries. Methods and results Twelve registries provided data in a systematic manner on outcomes in STEMI patients overall, and seven of these also provided data for P2Y12 receptor inhibitor-based dual antiplatelet therapy. The registrieswere heterogeneous in terms of site, patient, and treatment selection, as well as in definition of endpoints (e.g. bleeding events). All-cause death rates based on the data from 84 299 patients (9612 patients on prasugrel, 11 492 on ticagrelor, and 27 824 on clopidogrel) ranged between 0.49 and 6.68% in-hospital, between 3.07 and 7.95% at 30 days (reported in 6 registries), between 8.15 and 9.13% at 180 days, and between 2.41 and 9.58% at 1 year (5 registries). Major bleeding rates were 0.09-3.55% inhospital (8 registries), 0.09-1.65% at 30 days, and 1.96% at 1 year (only 1 registry). Fatal/life-Threatening bleeding was rare occurring between 0.08 and 0.13% in-hospital (4 registries) and 1.96% at 1 year (1 registry). Conclusions Real-world evidence from European contemporary registries shows that death, ischaemic events, and bleeding rates are lower than those reported in Phase III studies of P2Y12 inhibitors. Regarding individual P2Y12 inhibitors, patients on prasugrel, and, to a lesser degree, ticagrelor, had fewer ischaemic and bleeding events at all time points than clopidogrel-Treated patients. These findings are partly related to the fact that the newer agents are used in younger and less ill patients.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- Acute coronary syndromes
- Antiplatelet agents
- Clopidogrel
- Effectiveness
- Methodology
- Observational
- P2Y12 receptor inhibitors
- Prasugrel
- Real-world evidence
- Safety
- St-segment elevationmyocardial infarction
- Ticagrelor
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Danchin, Nicolas
-
Lettino, Maddale ...
-
Zeymer, Uwe
-
Widimsky, Petr
-
Bardaji, Alfredo
-
Barrabes, Jose A ...
-
visa fler...
-
Cequier, Angel
-
Claeys, Marc J.
-
De Luca, Leonard ...
-
Dörler, Jakob
-
Erlinge, David
-
Erne, Paul
-
Goldstein, Patri ...
-
Koul, Sasha M.
-
Lemesle, Gilles
-
Lüscher, Thomas ...
-
Matter, Christia ...
-
Montalescot, Gil ...
-
Radovanovic, Dra ...
-
Sendón, Jose Lop ...
-
Tousek, Petr
-
Weidinger, Franz
-
Weston, Clive F. ...
-
Zaman, Azfar
-
Andell, Pontus
-
Li, Jin
-
Jukema, J. Woute ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
European Heart J ...
- Av lärosätet
-
Lunds universitet